Pyrazole derivatives, as a class of heterocyclic compounds, possess unique chemical
structures that confer them with a broad spectrum of pharmacological activities. They have …

Direct oral anticoagulants (DOAC) have shown an upward prescribing trend in recent years
due to favorable pharmacokinetics and pharmacodynamics without requirement for routine …

Apixaban (Apx), an oral anticoagulant drug, is a direct factor Xa inhibitor for the prophylaxis
against venous thromboembolism. Apx has limited oral bioavailability and poor water …

Nanostructured lipid carriers (NLCs) have been proven to significantly improve the
bioavailability and efficacy of many drugs; however, they still have many limitations. These …

Apixaban (APX) is a direct inhibitor of factor X (FXa) approved for prophylaxis and treatment
of deep venous thrombosis and atrial fibrillation. Because FXa activates protease-activated …

Purpose This study aims to review the published literature concerning the use of novel oral
anticoagulants (NOACs) in the treatment and prevention of venous thromboembolism (VTE) …

Apixaban, an anticoagulant, is limited in its efficacy due to poor solubility, low bioavailability,
and extensive metabolism. This study investigates the application of nanostructured lipid …

Bicyclo [1.1. 1] pentylamines (BPCAs), emerging as sp3-rich surrogates for aniline and its
derivatives, demonstrate unique structural features and physicochemical profiles in …

A convergent synthesis of the anti-coagulant drug apixaban has been efficiently
demonstrated on a multi-gram scale. The synthetic route is noteworthy for its brevity and fact …

The common pathophysiology of acute coronary syndrome is usually thrombus formation
after rupture or erosion of the coronary artery plaque. The key goal of treatment is to resolve …